Solventum Co. (NYSE:SOLV) Holdings Raised by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Solventum Co. (NYSE:SOLV) by 26.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 230,435 shares of the company’s stock after purchasing an additional 47,547 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Solventum were worth $15,467,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Solventum by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company’s stock worth $1,074,591,000 after acquiring an additional 75,631 shares in the last quarter. State Street Corp lifted its position in shares of Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after acquiring an additional 185,938 shares in the last quarter. Geode Capital Management LLC boosted its stake in Solventum by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock worth $232,608,000 after purchasing an additional 128,317 shares during the period. Hotchkis & Wiley Capital Management LLC purchased a new position in Solventum during the 3rd quarter worth approximately $125,488,000. Finally, Boston Partners acquired a new stake in Solventum during the 4th quarter valued at $110,378,000.

Solventum Stock Performance

SOLV stock opened at $76.02 on Tuesday. The firm has a 50 day moving average of $75.56 and a two-hundred day moving average of $71.92. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92. The company has a market capitalization of $13.15 billion and a price-to-earnings ratio of 27.64. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SOLV. Wells Fargo & Company raised their target price on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Friday, February 28th. The Goldman Sachs Group lifted their target price on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Piper Sandler increased their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Mizuho boosted their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Finally, Morgan Stanley increased their target price on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.